Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 10/20 | 0.64 |
| ▸ | TYMS | P04818 | 7/20 | 0.64 |
| ▸ | GART | P22102 | 5/20 | 0.63 |
| ▸ | ATIC | P31939 | 3/20 | 0.63 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.63 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.63 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.63 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.63 |
| ▸ | FRK | P42685 | 1/20 | 0.63 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.63 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27994242 | 0.90 | DHFR (0.66) | DHFRTYMSGARTATICSHMT1 | |
| SCHEMBL27994239 | 0.90 | DHFR (0.66) | DHFRTYMSGARTATICSHMT1 | |
| SCHEMBL10109251 | 0.88 | DHFR (0.63) | DHFRTYMSGARTATICSHMT1 | |
| Pemetrexed SCHEMBL572065 | 0.82 | GART (0.73) | DHFRTYMSGARTATICSHMT1 | |
| Pemetrexed SCHEMBL7968 | 0.81 | GART (0.77) | DHFRTYMSGARTATICSHMT1 | |
| Pemetrexed SCHEMBL6034765 | 0.81 | GART (0.77) | DHFRTYMSGARTATICSHMT1 | |
| Pemetrexed SCHEMBL2549428 | 0.81 | GART (0.77) | DHFRTYMSGARTATICSHMT1 | |
| Pemetrexed SCHEMBL7969 | 0.81 | GART (0.77) | DHFRTYMSGARTATICSHMT1 | |
| SCHEMBL10123946 | 0.81 | GART (0.62) | DHFRTYMSGARTATICSHMT1 | |
| SCHEMBL17794005 | 0.81 | DHFR (0.72) | DHFRTYMSGARTATICSHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | DHFR 593/4885TYMS 775/4885GART 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.